Results for tag: "Ontak"

Ontak (denileukin diftitox) is a recombinant fusion protein used to treat cutaneous T-cell lymphoma (CTCL). It is a targeted therapy that works by binding to the CD25 antigen on the surface of malignant T-cells, causing them to die. It is administered intravenously and is approved for use in both the United States and Europe. Ontak is one of several drugs used to treat CTCL, a type of non-Hodgkin's lymphoma. Other drugs used to treat CTCL include bexarotene, vorinostat, and romidepsin. These drugs are used in combination with other treatments such as radiation and chemotherapy. Ontak is marketed by Eisai Inc. in the United States and by Pierre Fabre Medicament in Europe. Other companies involved in the market include Celgene Corporation, Merck & Co., and Novartis AG. Show Less Read more